Hiroshi Nomura Representative Director, President and CEO
Disclaimer Regarding Forward-looking Statements
This material contains forecasts, projections, targets, plans, and other forward-looking statements regarding the Group's financial results and other data. Such forward-looking statements are based on the Company's assumptions, estimates, outlook, and other judgments made in light of information available at the time of preparation of such statements and involve both known and unknown risks and uncertainties.
Accordingly, plans, goals, and other statements may not be realized as described, and actual financial results, success/failure or progress of development, and other projections may differ materially from those presented herein.
This document was prepared to explain the nature of Frontier Business; it is not intended to endorse any specific product or to make a commercial profit. Information contained herein includes material on devices and solutions that are under development or being planned for development, but such content is not intended as advertising or medical advice. Nor is it to be construed as including recommendations for such devices or solutions.
2
Frontier Business Domain
In anticipation of environmental changes in the future, such as the spread of preventive medicine and digital technology, Frontier Business is launched with the aim of providing new solutions to address social issues in the healthcare area other than pharmaceuticals
Global Specialized Player
Pharmaceuticals+Solutions
Global leader in 3 areas
Best in
Psychiatry
Medicine / Cell
Healthcare
Oncology Regenerative
class
Solution
&
focused
Therapy
(Frontier business)
Neurology
/ Cell
on value
in 2033
Aiming to establish Frontier Business as a growth engine in the medium to long term, following the group's pharmaceutical business
3
Establishment of Frontier Business Office: April, 2019
Focusing on areas in which synergies can be expected with the group's pharmaceutical
business
Psychiatry
Motor
Lifestyle
&
-related
Oncology
Dysfunction
Neurology
disease
Building a business foundation on, among others, core technologies (information, engineering, etc.) and networking (via alliances, investment in venture businesses, etc.)
Initiating and developing multiple pilot solution projects, including the coordination of initiatives for prevention, prediction, cure, and care
Exploring commercialization opportunities primarily in Japan, the U.S., and China
4
Future Vision for Frontier Business
Senior Executive Officer Hiroyuki Baba
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original document
Permalink
Disclaimer
Sumitomo Dainippon Pharma Co. Ltd. published this content on 08 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 September 2021 01:41:03 UTC.
Sumitomo Pharma Co., Ltd. (formerly Sumitomo Dainippon Pharma Co., Ltd.) specializes in development, manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceuticals (92.9%): for cardiovascular, gastrointestinal and infectious diseases, central nervous systems disorders and allergies treatment;
- other (7.1%): veterinary drugs, food additives, industrial chemical products, etc.
Net sales are distributed geographically as follows: Japan (39.8%), the United States (50.4%), North America (0.9%) and other (8.9%).